Novo Nordisk denied general conditional reimbursement for Wegovy in Denmark – again

The Danish Medicines Agency has been told for the second time that the price of the obesity drug is not in line with the effect it provides.

The reimbursement committee under the Danish Medicines Agency has recommended that Novo Nordisk’s obesity drug Wegovy is not granted general conditional reimbursement. This is the second time that the council has taken this stance.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs